Jun Qi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jun Qi has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Chang-Zhi Huang
Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
1 shared publication Chao Chen
The Institute of Clinical Pharmacology of Chinese PLA General Hospital, Beijing, China
1 shared publication- Chunfeng Qu
Department of Immunology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
1 shared publication DI Shen
Clinical Laboratory, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China
1 shared publication- Hong Zhao
Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
1 shared publication - Hongmei Zeng
National Central Cancer Registry & State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China
1 shared publication
Latest Publications
- Open Access
- 1 December 2017
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 65, 15-21
Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: Experience of the Chinese National Cancer Center
- 1 December 2017
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 65, 15-21
Open AccessContribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: Experience of the Chinese National Cancer Center
- Open Access
- 5 July 2016
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 46 (9) , 811-818
Serum microRNA expression profile as a diagnostic panel for gastric cancer
Previously, we identified six miRNAs that are differentially expressed in colorectal cancer compared with healthy controls. Here, we tested them in gastric cancer GC. We performed quantitative RT-PCR on serum samples from 92 patients with gastric cancer and 89 controls for the six miRNAs, and analyzed their risk scores to evaluate the diagnostic value of the serum miRNA profiling system. After a two-phase selection and validation process, five miRNAs were found to significantly differ in expression between gastric cancer samples and control samples, including miR-21, miR-31, miR-92a, miR-181b, and miR-203. Risk score analysis showed that this miRNA panel could distinguish gastric cancer cases from controls with high sensitivity and specificity. Under receiver operating characteristic curves, areas under the curve for tumor identification were 0.933 (95% confidence interval [CI]: 0.86–1.007) for the training set and 0.919 (95% CI: 0.863–0.975) for the validation set—markedly higher than those of carcinoembryonic antigen (0.624) and carbohydrate antigen 19-9 (0.603). The signature of these five miRNAs is a novel and noninvasive biomarker for gastric cancer, and could facilitate and simplify its diagnosis.
- 5 July 2016
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 46 (9) , 811-818
Open AccessSerum microRNA expression profile as a diagnostic panel for gastric cancer
Previously, we identified six miRNAs that are differentially expressed in colorectal cancer compared with healthy controls. Here, we tested them in gastric cancer GC. We performed quantitative RT-PCR on serum samples from 92 patients with gastric cancer and 89 controls for the six miRNAs, and analyzed their risk scores to evaluate the diagnostic value of the serum miRNA profiling system. After a two-phase selection and validation process, five miRNAs were found to significantly differ in expression between gastric cancer samples and control samples, including miR-21, miR-31, miR-92a, miR-181b, and miR-203. Risk score analysis showed that this miRNA panel could distinguish gastric cancer cases from controls with high sensitivity and specificity. Under receiver operating characteristic curves, areas under the curve for tumor identification were 0.933 (95% confidence interval [CI]: 0.86–1.007) for the training set and 0.919 (95% CI: 0.863–0.975) for the validation set—markedly higher than those of carcinoembryonic antigen (0.624) and carbohydrate antigen 19-9 (0.603). The signature of these five miRNAs is a novel and noninvasive biomarker for gastric cancer, and could facilitate and simplify its diagnosis.
- 14 January 2014
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 2 (2) , 207-211
Identification of immature granulocytes in cancer chemotherapy patients by cell counting vs. microscopic examination of blood smears
Tumor cell formation occurs through various mechanisms that may result in the growth of tumor blood vessels. Thus, novel methods are required to provide tumor therapy. The aim of the present study was to investigate the reliability of the abnormality‑indicating alarm information provided by the automatic hematology analyzer in the measurement of immature granulocytes (IG) and assess the factors involved. The quality control groups at three concentration levels were repeatedly determined within 20 days to observe the within‑run precision. The quality control groups at two concentration levels were repeatedly determined within 20 days to observe the between‑run precision. The results obtained by the two methods were compared and the reliability of IG measurement using the hematology analyzer was analyzed. Additionally, IG parameters of 120 venous blood specimens collected from cancer patients were measured by cell counting using a hematology analyzer and stained blood smears were observed. The within‑run precision experiment showed that the coefficient of variation (CV) values of the IG percentage in the high, middle and low concentration levels were 3.62, 6.75 and 13.69%, respectively, while the CV values of the IG percentage in the two‑level between‑run precision experiment were 5.6 and 7.1%, respectively. All of the CV values were <15% and within the permitted range. The true‑positive rates obtained using the hematology analyzer in the IG≤1%, 110% groups were 11.5, 65.4 and 95.0%, respectively, and the false‑negative rates were 0. The IG percentages obtained through the hematology analyzer measurement and from the microscopic observation were (6.98±11.18) and (9.36±20.71)%, respectively. Results of the correlation analysis revelaed that there was an excellent correlation between the two methods (r=0.1364). A significant difference between the two methods was observed using the signed‑rank test (P=0.001). Manual microscopic observation is essential for the IG specimen that has been measured using an automatic hematology analyzer and has received an abnormality alarm. For cancer patients who receive chemotherapy, this application helps to provide laboratory data for clinical disease diagnosis and treatment monitoring.
- 14 January 2014
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 2 (2) , 207-211
Identification of immature granulocytes in cancer chemotherapy patients by cell counting vs. microscopic examination of blood smears
Tumor cell formation occurs through various mechanisms that may result in the growth of tumor blood vessels. Thus, novel methods are required to provide tumor therapy. The aim of the present study was to investigate the reliability of the abnormality‑indicating alarm information provided by the automatic hematology analyzer in the measurement of immature granulocytes (IG) and assess the factors involved. The quality control groups at three concentration levels were repeatedly determined within 20 days to observe the within‑run precision. The quality control groups at two concentration levels were repeatedly determined within 20 days to observe the between‑run precision. The results obtained by the two methods were compared and the reliability of IG measurement using the hematology analyzer was analyzed. Additionally, IG parameters of 120 venous blood specimens collected from cancer patients were measured by cell counting using a hematology analyzer and stained blood smears were observed. The within‑run precision experiment showed that the coefficient of variation (CV) values of the IG percentage in the high, middle and low concentration levels were 3.62, 6.75 and 13.69%, respectively, while the CV values of the IG percentage in the two‑level between‑run precision experiment were 5.6 and 7.1%, respectively. All of the CV values were <15% and within the permitted range. The true‑positive rates obtained using the hematology analyzer in the IG≤1%, 110% groups were 11.5, 65.4 and 95.0%, respectively, and the false‑negative rates were 0. The IG percentages obtained through the hematology analyzer measurement and from the microscopic observation were (6.98±11.18) and (9.36±20.71)%, respectively. Results of the correlation analysis revelaed that there was an excellent correlation between the two methods (r=0.1364). A significant difference between the two methods was observed using the signed‑rank test (P=0.001). Manual microscopic observation is essential for the IG specimen that has been measured using an automatic hematology analyzer and has received an abnormality alarm. For cancer patients who receive chemotherapy, this application helps to provide laboratory data for clinical disease diagnosis and treatment monitoring.